What to expect from PEGS Europe 2023: Day 3
Drug Discovery World
NOVEMBER 13, 2023
Stefan Warmuth, PhD, Vice President, Head CMC, Numab Therapeutics, on: ‘Update on Numab’s affinity-balanced PD-L1x4-1BBxHSA trispecific tumour-targeted immunotherapy’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.
59 
Let's personalize your content